BidaskClub lowered shares of Chromadex (NASDAQ:CDXC) from a buy rating to a hold rating in a research report released on Tuesday morning.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright set a $8.00 price objective on shares of Chromadex and gave the company a buy rating in a research report on Tuesday. ValuEngine cut shares of Chromadex from a hold rating to a sell rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Chromadex from a buy rating to a hold rating in a research report on Wednesday, November 29th. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Chromadex in a research report on Monday, September 25th. They issued a buy rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $7.50.

Shares of Chromadex (CDXC) traded down $0.33 during trading hours on Tuesday, hitting $5.85. 585,000 shares of the company were exchanged, compared to its average volume of 293,440. The company has a current ratio of 5.03, a quick ratio of 4.12 and a debt-to-equity ratio of 0.01. Chromadex has a twelve month low of $2.26 and a twelve month high of $7.24. The company has a market cap of $332.72, a P/E ratio of -41.78 and a beta of 1.37.

Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Chromadex had a negative net margin of 21.89% and a negative return on equity of 47.30%. analysts expect that Chromadex will post -0.15 earnings per share for the current fiscal year.

In other Chromadex news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the company’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $6.52, for a total value of $185,031.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder River Ventures Ltd Champion bought 731,707 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was purchased at an average price of $4.10 per share, with a total value of $2,999,998.70. The disclosure for this purchase can be found here. 11.59% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its stake in shares of Chromadex by 870.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after acquiring an additional 163,817 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in shares of Chromadex in the 3rd quarter worth approximately $128,000. Finally, Granite Investment Partners LLC lifted its stake in shares of Chromadex by 5.7% in the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after acquiring an additional 13,599 shares during the period. 6.08% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/17/chromadex-cdxc-stock-rating-lowered-by-bidaskclub.html.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.